The approach described here is similar to the strategy used in the design of chemically modified peptides to inhibit both the PDZ3 domain of postsynaptic density protein 95 (PSD-95) for the treatment of stroke, and the PDZ domain of the GAIP-interacting protein, C-terminus (GIPC) for cancer therapy [13], [14]. This evidence concerns the gene DLG4 and Stroke.